Categories: Health

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

 | Source: RxSight, Inc.

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

RxSight’s management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

GlobeNews Wire

Recent Posts

Alimentaria+Hostelco successfully closes its most international edition

BARCELONA, Spain, March 27, 2026 /PRNewswire/ -- The leading trade fair platform for the food,…

7 hours ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

March 27, 2026 10:40 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., March 27, 2026…

12 hours ago

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability…

12 hours ago

Huize Holding Limited Reports Unaudited Financial Results for the Second Half and Full Year 2025

SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or…

18 hours ago

Global study shows energy industry ramping up investment in autonomous operations by 2030 as AI reshapes performance

Study of 400 senior energy and chemicals leaders across 12 countries signals a tipping point:…

18 hours ago